Alan Lader
Direttore Tecnico/Scientifico/R&S presso CITIUS PHARMACEUTICALS, INC.
Profilo
Alan Lader is currently the SVP, Head-Clinical Operations & Quality Assurance at Citius Pharmaceuticals, Inc. Previously, he worked as the Director-Clinical Operations at Ischemix, Inc. Lader received his undergraduate degree from Syracuse University, his graduate degree from Rensselaer Polytechnic Institute, and his doctorate from the University of South Carolina School of Medicine.
Posizioni attive di Alan Lader
Società | Posizione | Inizio |
---|---|---|
CITIUS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/03/2016 |
Precedenti posizioni note di Alan Lader
Società | Posizione | Fine |
---|---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Corporate Officer/Principal | - |
Formazione di Alan Lader
Syracuse University | Undergraduate Degree |
Rensselaer Polytechnic Institute | Graduate Degree |
University of South Carolina School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
CITIUS PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
- Borsa valori
- Insiders
- Alan Lader